• Vaccines Development, Regulations And Manufacturing Part-2

    In Part 2, we will review vaccine processes with examples based upon influenza vaccine, inactivated Polio vaccine and an overview of the different types of vaccine production processes from cell expansion, USP and DSP, to the formulation and filling operations to make the finished product. We will talk about vaccine production facilities, how equipment is integrated their operating principles and biological safety levels for containment. Finally, we will look at the vaccine industry today, the supply chain and globalization, and how important vaccines are in pandemic preparedness, availability, and time to market.

  • Improve Bioprocessing Efficiency With A Standardized Automation Platform

    Designed specifically for the biomanufacturing industry, Cytiva's Figurate automation is a portfolio of automation platform solutions powered by the reliability of Emerson’s DeltaV.

  • High-Quality Chromatography System Meets Predesigned DeltaV For Integrated Manufacturing

    Cytiva’s pre-defined automation solution, Figurate™️, is now available as a turnkey solution by combining our industry-leading ÄKTA™️ process chromatography system with the reliability of the DeltaV DCS platform.

  • Achieving Business Continuity In Pharma During COVID-19 Restrictions

    To ensure business continuity during COVID-19 restrictions, we developed a virtual factory acceptance testing solution that allowed SaudiVax to advance their manufacturing plan.

  • How To Prepare For Future Viral Vector Manufacturing Technologies And Platforms

    The challenges and shortage of vector production reflect the fact that these materials and products are having such strong clinical success. Let’s celebrate the reason for this demand. To meet it, we need to industrialize and rethink how we transition from what has historically been carried out in translational clinical centers at smaller scale, using flasks and open systems, towards commercial production and methodologies.

  • Effectively Managing Data In Process Development

    Addressing data management challenges during drug development requires an understanding of today’s shortcomings and the factors to consider when adopting a solution to overcome them.

  • Covid-19 Impact On Bioprocessing: PART 3 Long-Term Changes

    Although suppliers have proven themselves rather robust in their dealing with the pandemic and business is continuing generally uninterrupted, there will be significant long-term changes.

  • Re-Imagining Vaccine Manufacturing To Address Global Health Challenges

    In the last decade, biopharmaceutical industries have mobilized quickly in response to pandemics. Developing vaccines and manufacturing large doses in response to an emergency is often constrained by existing platforms and facility configurations. Learn how vaccine manufacturing can evolve to tackle future global health challenges.

  • COVID-19 Impact On Bioprocessing: PART 1 Accelerating Trends

    Because of the urgent demand for treatments, vaccines and assays, the pharmaceutical and biotech industries are experiencing disruptive, often chaotic, increased demands on resources. 


  • Genderless AseptiQuik® Large Format 3/4", 1" and 1½" sanitary Connectors enable quick and easy sterile connections, even in non-sterile environments. The easy-to-use genderless design simplifies system integration and minimizes the risk of operator error. The connector's robust construction provides enhanced user confidence and reliable performance without the need for clamps, fixtures or tube welders. Biopharmaceutical manufacturers benefit from a full range of interchangeable 3/4" to 1½" flow solutions for production environments with the quality and market availability they expect from the leader in single-use connection technology.

  • In biomanufacturing the only certainty is risk and the only constant is change. Technology is pushing new frontiers, new markets are opening up across the globe, and new competition is creating new levels of urgency—all under the ever more watchful eye of regulators.

  • To fulfill the increasing demand of life-saving solutions for patients' lives all over the world, we decided to drive forward with building our new facility, Plant 4. Our accumulated expertise is implemented with the latest technologies and innovation, so that Plant 4 will be able to serve as part of your global presence, becoming your future biomanufacturing hub.

  • Genderless AseptiQuik® L Connectors enable quick and easy sterile connections, in large-volume, high-flow production environments. The largeformat, 3/4" and 1" genderless design simplifies system integration and minimizes the risk of operator error.

  • As the biopharma industry identifies faster and more efficient ways to deliver drugs to patients, such as break-through and fast track designations for accelerated approval, these progresses create pressure on both large and small drug manufacturers. As development timelines shorten, decisions related to drug commercialization need to be taken earlier, when key results are not yet available. And deciding on the scale and type of facility to build without complete data can create substantial risks with costly consequences.